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Otitis media (OM) with mucoid eﬀusion, characterized by mucous cell metaplasia/hyperplasia in the middle ear cleft and thick
ﬂuid accumulation in the middle ear cavity, is a subtype of OM which frequently leads to chronic OM in young children. Multiple
factors are involved in the developmental process of OM with mucoid eﬀusion, especially disorders of mucin production resulting
frommiddleearbacterialinfectionandEustachiantubedysfunction.Inthisreview,wewillfocusonseveralaspectsofthisdisorder
by analyzing the cellular and molecular events such as mucin production and mucous cell diﬀerentiation in the middle ear mucosa
with OM. In addition, infectious agents, mucin production triggers, and relevant signaling pathways will be discussed.
1.Introduction
Otitis media (OM) is characterized by the production of
mucins in the middle ear mucosa. There are abundant
mucouscells(gobletcells)intheinﬂamedmiddleearmucosa
whenever there is inﬂammation in the middle ear cavity [1–
7]. In a typical case of purulent OMor acute bacterial middle
ear infection, one thing an ENT clinical doctor would notice
is mucus, together with pus, in the middle ear cavity and/or
the external canal if the ear drum is perforated. In a typical
case of chronic OM, more often than not, otolaryngologists
would observe slimy substance or sticky mucus, like a rubble
band, accumulated in the middle ear cavity. Similarly, one
would see the same situation in the chronic mastoiditis.
There is always mucus production and accumulation when
there is an infection in the middle ear and mastoid mucosal
system. This excessive mucous production interferes with
mucosal function and plays a negative role in recovery
of middle ear function and, therefore, contributes to the
development of chronic OM. Many ENT doctors consider
mucouscellmetaplasia/hyperplasiachronic,irreversible,and
intractable clinically.
Mucous cell metaplasia/hyperplasia is a pathological
term that describes an increased mucous cell population or
density in the upper respiratory mucosa upon infections
and/or other stimuli. It is usually determined by histochem-
ical examination with Alcian Blue-Periodic Acid Schiﬀ (AB-
PAS) stain which identiﬁes large molecular weight glycopro-
teins (i.e., macroglycoconjugates or macroglycoproteins) in
a cell. These macroglycoconjugates are heavily glycosylated
proteins (mucins) which are a family of glycoproteins up to
20 members. A mucin glycoprotein typically consists of 10–
15% protein back bones and up to 90% sugar side chains by
mass [8, 9]. Mucins, together with mucin chaperones such as
trefoil factors, are tightly packed into mucous granules that
are positive for AB-PAS stain (Figure 1).
In the middle ear, mucous cell metaplasia/hyperplasia is
a cardinal pathology in response to middle ear inﬂammatory
and/or immune reactions [5]. Similar responses frequently
occur in the airways in response to harmful insults [10].2 International Journal of Otolaryngology
Figure 1:Mucouscellmetaplasia/hyperplasia isidentiﬁedwithAB-
PAS stain in a piece of middle ear mucosa (from a chronic OM
patient) which contains abundant mucous cells (arrows, deep blue
areas) and accumulated mucin glycoproteins in the central area of
the gland-like structures. Ampliﬁcation, ×20.
In the lung, mucous cell metaplasia/hyperplasia can be life
threatening due to its capability to block airway lumen by
secreting a large amount of mucus [9, 11–15]. Particularly,
this condition is referred to as chronic obstructive pul-
monary diseases (COPDs). Cigarette smoking is the leading
cause of COPD by stimulating mucus production of goblet
cells.
The reason for mucous cell metaplasia/hyperplasia is
multifactorial [16]. External stimuli such as chronic micro-
biological infections, long-term exposure to other irritants
such as cigarette smoking, air pollution, and certain gases
such as SO2 can trigger mucous cell metaplasia/hyperplasia
in the respiratory tract mucosa [17, 18]. Clinically, bac-
terial infection in the middle ear is the most common
etiology. In children, the most common bacterium involved
in mucous cell metaplasia/hyperplasia is S. pneumococcus
and its metabolites. Indeed, OM with mucoid eﬀusion
is more frequently seen in child cases than adult ones
[19]. Experimentally, pneumococcal infection in the middle
ear of rats is prone to the development of mucous cell
metaplasia/hyperplasia.
In contrast, H. inﬂuenza tends to develop ﬁbrotic dis-
orders than mucous cell metaplasia/hyperplasia in animal
experimental OM models [20, 21]. Biologically, pepti-
doglycan polysaccharides (PGPS, metabolites of S. pneu-
monae) stimulates epithelial proliferation whereas endotoxin
(metabolites of H. inﬂuenza) promotes epithelial cell death
in cultured middle ear epithelial cells, causing necrosis or
apoptosis of the middle ear epithelial cells (Figure 2). This
may explain why S. pneumoniae tends to cause mucous
cell metaplasia/hyperplasia. However, both Gram-positive
and -negative bacteria are potent inducers of mucous cell
metaplasia/hyperplasia.Tos and Caye-Thomasen observed
an increased goblet cell density in acute OM, variable by
causative pathogen [22].
It is well recognized that mucous cell metapla-
sia/hyperplasia occurs in the acute event of middle ear infec-
tion but continues to deteriorate when there are recurrent
or chronic OM. It is diﬃcult to fully restore the mucous
cell population or density back to the baseline level once
mucous cell metaplasia/hyperplasia occurs in the middle ear
mucosa.Anepisodeofmiddleearinfectionalwaysaddssome
gobletcellstothemucosaeventheinfectionevenislonggone
[22, 23].
Under normal conditions, few goblet cells exist in the
middle ear cavity. These goblet cells are usually located in
the oriﬁce of the Eustachian tube, the partial promontory,
and hypotympanic areas, so called “ciliated track.” Goblet
cells increase dramatically following an acute middle ear
infectionoranacuteonsetofchronicOM.Theseproliferated
goblet cells are all over the entire middle ear mucosa, not
limited to the ciliated tract. Unlike ordinary epithelial cells,
goblet cells are an integral part of the innate immune system.
Therefore, maintenance of a stable goblet cell population
in the upper respiratory tract including the middle ear
epithelium is very important. It is observed that goblet
cells are protected from apoptosis by a transcription factor
called Id1 which keeps goblet cells alive on a long-term basis
(approximately months). That is the reason why mucous cell
metaplasia/hyperplasia remains in the diseased mucosa for a
while (weeks to months after infections are dissolved).
Clinically, the disease mechanism for mucous cell meta-
plasia/hyperplasia is not clear, but perceivably it involves
persistent stimuli in the middle ear mucosa. Without
repeated stimuli of bacteria or bacterial metabolites, mucous
cell metaplasia/hyperplasia does not occur. Under normal
conditions, transient stimuli do stimulate the diﬀerentiation
ofmucouscellsinthemiddleearmucosa,buttheactiondoes
not last for too long. For example, injection of middle ear
pathogens into the rat middle ear cavity induces transient
mucous cell metaplasia/hyperplasia which lasts for weeks to
months and then gradually subsides [24]. In other words,
mucous cell metaplasia/hyperplasia occurs because there are
chronic or recurrent stimuli persistently in the middle ear
mucosa.
However, the stimuli may be derived from chronic
infectionsandsometimejustfrombacterialmetabolites.One
example is OM with mucoid eﬀusion; frequently, there is no
active infection in the middle ear cavity. It is well recognized
that some dead bacterial cell wall fragments or metabolites
are suﬃcient to keep the middle ear mucosa in a state of
mucous cell metaplasia/hyperplasia.
2. MucinDysregulationinOM
The ﬁrst thing one would notice is that mucus is accu-
mulated in the middle ear cavity when mucous cell meta-
plasia/hyperplasia occurs in the middle ear mucosa. It is
frequently referred to as “glue ear” when the tympanic
membrane is intact and mucins are accumulated in the
middle ear cavity. In chronic OM or postsurgery patients, it
is often referred to as “wet ear” in an open middle ear cavity
because of continuous production of mucins in the diseased
middle ear mucosa and persistent secretion into the surface
of the middle ear mucosa. It has long been speculated that
mucin upregulation is the ﬁrst step for the epithelial cells to
become mucous cells.International Journal of Otolaryngology 3
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Figure 2: Pneumococcal cell wall component peptidoglycan-polysaccharides (PGPSs) stimulate the proliferation (a) of rat middle ear
epithelial cells whereas endotoxin (LPS) causes the death of the cells (b) compared with carrier treated cells (c). Cells were incubated with
PGPS at 20ng/mL for 6 hours and stained with PCNA antibody. Brown in color indicates cell nuclei with positive PCNA antigen.
Initially, those epithelial cells, rich in mucin production,
remain nonmucous in terms of phenotypes, rather, mucin-
producing cells. Mucin-producing cells are not necessarily
mucous cells. In the upper respiratory tract, ciliated cells also
produce limited amount of mucins, membrane-bound or
secreted. Anyway, these mucin-producing cells by deﬁnition
are not mucous cells, but they have the potential to become
mucous or goblet cells if mucin production is further
upregulated to a point at which cells produce only mucins
and mucin chaperones but no others. If the origin of
these cells is from ciliated cells, this is biologically called
transdiﬀerentiation of mucous cells.
Under normal conditions, the origin of mucous cells is
from epithelial stem cells above the basement membrane
[25, 26]. Transdiﬀerentiation occurs because there is an
emergent need of mucous cells to secret mucins to discharge
invading microorganisms. That is part of the innate immune
response. In such a cellular crisis, there is no suﬃcient time
for normal epithelial stem cells to respond and diﬀerentiate
into mucous cells step by step. It has been noted that
under normal conditions, the middle ear mucosa is not
populated with mucous cells because of relatively clean and
safe environments.
It has been known that approximately 20 mucin genes
have been identiﬁed, and 12 out of these genes have been
shown to be expressed in the respiratory tract [9]. In terms
of mucin(s) being upregulated, it is becoming clear that
MUC5B is the predominant one. The recent work done
by Preciado et al. has proved that MUC5B is abundant
in the majority of chronic OM patients [5, 27, 28]. This
is considered unusual because MUC5B is a major mucin
expressed in submucosal glands (mucous cells) not in
epithelial mucous cells in the entire upper respiratory tract.
Occasionally, MUC5AC may be upregulated in OM [28].
From this viewpoint, one would argue that chronic OM
triggers gland-like mucous cell diﬀerentiation in response to
middle ear infections [29]. Indeed, in the surgical samples
with chronic OM or mastoiditis, it has been observed
that gland-like structures with abundant mucous cells are
pathologically identiﬁed in the middle ear and mastoid area
[30]. Gland-like structures are often observed in chronic
OM patients (referred to as Figure 1). Consistent with this,
in situ hybridization clearly demonstrated that MUC5AC-
positive mucous cells are populated in the upper respiratory
epithelium including the Eustachian tube whereas MUC5B-
positive mucous cells are populated in the mucous glands of
the upper respiratory epithelia (Figure 3).
In contrast, middle ear epithelial cells are negative
for the MUC5AC mRNA transcripts but spotty MUC5B
mRNA transcripts are identiﬁed [4, 5]. This tells us that
a transitional process of mucin members from the airway
to the middle ear cavity occurs. This observation was
conﬁrmed recently by Preciado et al. that MUC5B mucin
is predominant in chronic OM patients [27, 28]. However,
other mucins such as MUC2 may be involved in middle ear
mucusofanimalmodels[31,32],buttheiramountislimited
orundetectableinhumansifany[4,5].Ithasbeennotedthat
mucin quantiﬁcation and comparison is notoriously diﬃcult
and at the best semiquantitative. This is because of the high
level of glycosylation which represents a posttranslational
modiﬁcation.
In a mucous cell, soluble mucins are secreted onto the
cell surface under the direction of trefoil factors [33]. Soluble
mucins expressed in mucous cells of the Eustachian tube
epithelium include MUC5B and MUC5AC under normal
conditions [4] whereas mucin expressed in mucous cells of
the middle ear epithelium under chronic OM conditions is
predominantly MUC5B in humans [4, 34]a n dM u c 2a n d
Muc5ac in rodents [31, 35]. MUC4 and MUC1 membrane-
b o u n dm u c i n sa r ei n v o l v e di nO Mb u tn o tm a j o ro n e s .
MUC5AC, MUC5B, MUC2, and MUC6 are known to be
clustered at a locus on chromosome 11p15.5 in human [36],4 International Journal of Otolaryngology
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Figure 3:MucinsMUC5ACandMUC5BaretwopredominantmucinsinthemiddleearandEustachiantubeareas.(a)MUC5ACistypically
expressed in the epithelial cells of the Eustachian tube. (b) MUC5B is predominantly expressed in the mucous cells of submucosal glands.
(c) Control for in situ hybridization in (a) and (b). Note: Black dots indicate the mRNA transcripts for MUC5AC or MUC5B.
bearing similar properties and functions of soluble mucins.
MUC5B in humans responds to chronic stimuli [28, 34],
while Muc2 in rodents responds to acute stimuli such as
inﬂammatory cytokine tumor necrosis factor alpha (TNFα)
[37].
As mentioned above, there are approximately 20 mucin
genes currently being identiﬁed from the human body. They
are either secretory mucins or membrane-bound mucins.
The former is a class of mucins that are synthesized as
monomers and then assembled into dimers or trimers in a
head-to-head or a head-to-tail manner to form polymers.
These mucins comprise mucous networks together with
TFFs and spread around after secretion to the surface
for protection of mucosal epithelial cells. On a smear,
one can clearly observe mucous strings and witness their
polymerization of soluble mucins.
Under a microscope, mucous strings are networked
substances (Figure 4). Under an electromicroscope, mucin
strings are linked head-to-head, forming polymers (Figure
5). Representative secretory mucins are MUC2, MUC5AC,
MUC5B, MUC6, and so forth. The secretory mucin lacks a
transmembrane domain and is, thus, doomed to be secreted.
Membrane-bound mucins are a class of glycoproteins which
are anchored directly to the bilayer of the cell membrane and
prevent the epithelial cells directly from contacting with bac-
teria, viruses, or other particles. Representative membrane-
bound mucins are MUC1, MUC3, MUC4, MUC7, and so
forth.
3.MucusGelComposition inOM
Mucus is mainly comprised of mucins [4, 5, 38–41]w h i c h
impart viscous elastic and gel-forming properties to mucus
[11–15]. The major mucins participate in the mucus gel
and are secretory (soluble) mucins because of their water-
soluble property. These soluble mucins are synthesized in
mucous cells, stored in mucous granules, and then secreted
onto the surface of epithelial cells by a regulated exocytosis
which requires an external signal, a speciﬁc sorting signal on
the vesicles, a clathrin coat, and an increase in intracellular
calcium.
Figure 4: Mucous strings are networked substances under a
microscope. Mucous granules are released from cultured mucous
cell clone derived from HT-29, and mucous strings are stained blue
on the cultured cell surface by AB-PAS. bar 50μm.
Occasionally, membrane-bound mucins such as MUC4
may participate in the mucus of middle ear eﬀusion [5,
42] because these membrane-bound mucins are truncated
by enzymes from bacteria and/or inﬂammatory cells and
releasedintomiddleeareﬀusions.Membrane-boundmucins
are biologically designed for cellular adhesion, pathogen
binding/shielding, surface protection, and signal transduc-
tion [43, 44]. In addition, water, ions, lipids, and proteins
such as mucin chaperones are integral parts of the mucus.
In a mucin, sugar side chains (glycans, both O-glycans
and N-glycans) can make up as high as 90 percent of the
total protein by mass. O-glycosylation is a major part of
mucin biosynthesis and requires an N-acetylgalactosaminyl
peptidyltransferase. It occurs in the central region of a
mucin molecule where there are numerous tandem repeats
(typically doszens to several hundred). N-glycosylation
typically occurs in the both end regions [9]. Recently, a
newly characterized linkage of C-mannose to tryptophan
(i.e., C-mannosylation) was identiﬁed in MUC5AC and
MUC5B mucins synthesized in vitro [45]. Usually, mucin
glycanscontributetotheviscosityofmucins.Themoresugar
side chains a mucin contains, the more sticky or viscous a
mucin is. Sugar side chains of a mucin contribute to the gel
properties of mucus. Not only do mucins serve the functionInternational Journal of Otolaryngology 5
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Figure 5:Mucinmonomersarelinkedinahead-to-headmannerin
a mucous gel, which is a basis for forming a mucous gel. The inserts
in (a) and (b) represent ampliﬁcations of a head-to-tail linkage (a
node-like structure, (a)) or a mucin backbone (a twisted rope-like
structure, (b)).
of protection, but they also act as lubricants and are integral
structural components of the mucociliary transport system.
Functionally, the sugar side chains act as receptors on cell
surfaces that wrap invading microorganisms.
Main mucin chaperones are trefoil factors (TFFs) [33]
which are represented by three members: TFF1(pS2),
TFF2(hSP), and TFF3(ITF) [46]. Among them, TFF3 is
expressed predominantly in the mucous cells of the small
and large intestine. Under diseased conditions, all the TFF
members can be expressed [47]. We have recently conﬁrmed
the expression of TFFs in mouse middle ear epithelial cells
(Figure 6).Inthehumangut,TFFsandmucinsarefrequently
coexpressedinmucouscellsinacloselyrelatedmanner.TFF1
with MUC5AC, TFF2 with MUC6, and TFF3 with MUC2
[48]. Other mucin chaperones include beta-defensins [49],
secretory IgA [50], and lactoferrin [51], which also deserve
attention.
It is not clear whether the same relationship exists in
the middle ear mucous cells. The TFF motif contains a
hydrophobic binding pocket that could represent a binding
site for sugar side chains of mucins, probably the oligomeri-
sation domain (also called cysteine rich von Willebrand
factor VWF/domain) of mucins, a common domain to
all mucins, located in C- or N-terminal domains that
permits disulﬁde bond to be formed between adjacent
mucins. With addition of TFFs to mucins plus mucin itself
multimerisation, the end result is the formation of a mucus
gel with high viscosity [5, 52].
4. Mucoid EffusioninOM
One of the manifestations of mucous cell metapla-
sia/hyperplasia is accumulation of mucoid eﬀusion in the
middle ear cavity [4, 29, 34, 53–57]. It is natural, on one
hand, that mucus accumulated in the middle ear cavity if
the Eustachian tube is not functional. On the other hand,
excessive production of the mucus itself can cause the
accumulation of mucus in the middle ear cavity even though
the Eustachian tube is functional. The reason is that the
viscosity of mucus secreted by the middle ear mucous cells,
especially MUC5B mucin, is very high. MUC5B is one of
the most viscous mucins because of its size and capability
to form multiple molecules head-to-head as shown in
previous reports [4, 5]. It is known that mucins are linked
togetherbyhead-to-headorhead-to-tailinadimerortrimer
manner. Other nonmucin molecules may form noncovalent
interactions with mucins. The detailed linkage between
individual mucins in the intestine for secreted mucins has
been proposed as linear-polymer (N-terminal dimerization)
or N-terminal-trimer netwok (N-terminal trimerization)
models by McGuckin and coworkers [15]. While MUC5B
mucins are chained together in a long string or network
[4, 5, 15], this makes middle ear mucus very viscous and
diﬃcult to discharge.
One may argue that the dysfunction of the Eustachian
tube or the physical obstruction of the Eustachian tube
(ETO) may also cause mucous cell metaplasia/hyperplasia.
This issue has been studied recently in our laboratory and
others. We have shown that ETO alone mainly induces
accumulation of serous ﬂuid in the middle ear cavity but
rarely induces mucous cell metaplasia in pathogen-free rats
[20, 58] whereas mucous cell metaplasia/hyperplasia may
be induced in non-pathogen-free rats. This diﬀerence may
be best explained by priming of the middle ear mucosa by
pathogens prior to ETO.
This notion is further supported by the observation
in cats that mucous cell metaplasia/hyperplasia with thick
eﬀusion in the middle ear cavity is readily induced by ETO
alone (unpublished data at the Otopathology Lab, University
of Minnesota). The reason for this appears to be that the
middle ear of cats is frequently colonized with bacteria
from the upper respiratory tract due to their relatively short
Eustachian tube. It has been shown, on one hand, that
pneumococcus-induced middle ear infection in rats results
in higher goblet cell numbers compared with H. inﬂuenzae-
induced middle ear infection.
On the other hand, multiple challenges with pneumo-
coccus in the middle ear induced more goblet cells than a
single challenge in the middle ear of pneumococcus [20],
suggestingthatrepeatedmiddleearpneumococcalinfections
or a long-term exposure to pneumococcal cell envelope are
important determinants for the development of mucous cell
metaplasia/hyperplasia in OM. In these experiments, it has6 International Journal of Otolaryngology
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Figure 6: Mucin chaperones are inducible in cultured mouse middle ear epithelial cells. (a) TFF1, TFF2, and TFF3 are barely detected by
reverse transcription polymer chain reaction (RT-PCR) in cultured mouse middle ear epithelial cells and are induced by TNFα and RA for
two weeks (TR). (b) TFF3 is induced by TR treatment for two weeks as judged by immunohistochemistry. Ctrl, control; bar = 5μm.
beennotedthatbacterialremnantsmayremaininthemiddle
ear cavity despite the absence of viable bacteria, similar to
the human setting where bacterial cell envelope components
were present in the middle ear cavity although bacterial
cultures were sterile [59, 60].
5.TriggersofMucousCell
Metaplasia/Hyperplasia
It is well accepted that middle ear infection triggers mucous
cell metaplasia. Experimentally, we and others have shown
that bacterial infection or cytokine challenge of middle
ear mucosa results in mucous cell metaplasia/hyperplasia
[20, 24, 37, 58, 61–63]. Clinically, chronic OM with mucoid
eﬀusion is frequently preceded by upper respiratory tract
infection [19]. An inﬂammatory cascade of events typically
activates inﬂammatory cells, including but not limited
to eosinophils, lymphocytes, and mast cells. It causes an
immune response.
Thisinﬂammatoryreactionnotonlymediatesexpression
of the mucin genes such as MUC5B but also mucous
cell metaplasia/hyperplasia via an inﬂammatory mediator-
dependent mechanism [5]. The middle ear epithelial mucosa
of rodents usually contains few mucous cells as judged
by histology or whole mount middle ear mucosa. Many
inﬂammatory mediators that cause mucous cell metapla-
sia/hyperplasia in OM were originally deﬁned in rodents
[20, 58] and subsequently veriﬁed in humans [64].
Cytokines are well known to be involved in mucous
cell metaplasia/hyperplasia, especially proinﬂammatory
cytokines and T-helper 2 (Th2) subset-derived cytokines.
These cytokines include TNFα [37, 58, 65, 66], IL-13
[67–69], IL-10 [70], IL-8 [71], IL-9 [72], IL-4 [73], and
so forth. Loss of cytokines in mice such as IL-10 results in
reduced mucous cell metaplasia/hyperplasia in the middle
ear of mice although it does not completely deplete the
mucous cell population (Figure 7). It is noted that IL-9,
IL-8, and IL-4 overexpression in the trachea increases
mucous cell metaplasia/hyperplasia, but knockout of
IL-9 did not aﬀect the development of allergen-induced
mucous cell metaplasia/hyperplasia [74] .T h er o l eo f
Th2 lymphocytes in mucous cell metaplasia/hyperplasia
was determined by animal models in which marked
mucous cell metaplasia/hyperplasia occurs in mice that
received Th2 cells but not in mice that received Th1 cells
[75].
In T-, B-, and mast cell-deﬁcient mice, reconstitution
of CD4+ cells restores allergen-induced airway hypersen-
sitivity, allergic inﬂammation, and mucous cell metapla-
sia/hyperplasia [76]. It suggests that mucous cell metapla-
sia/hyperplasia is dependent upon a subset of CD4+ Tc e l l s
(regulatory, natural killer, or cytotoxic T cells). Possibly, it is
a subpopulation of Th2 cells and their cytokines that medi-
ate allergen-induced mucous cell metaplasia/hyperplasia.
Theoretically, inﬂammatory mediators that strengthen Th2
cell functions and increase expression of Th2 cytokines are
involvedinmucouscellmetaplasia/hyperplasiaintheclinical
setting of allergy. However, this does not necessarily mean
that Th2 cytokines are indispensable in the inﬂammatory
setting.
Asthma is also known to trigger mucous cell metapla-
sia/hyperplasia in the respiratory tract. Typically, in asthma
patients, mucous cell metaplasia/hyperplasia in peripheral
airways is consistent pathologic characteristics of bronchial
asthma [77]. It follows a similar paradigm as seen in
bacterial infection; that is, systemic sensitization to allergens
followed by repeated exposure to allergens causes an allergic
inﬂammation. This reaction results in Th2 cytokine release
and subsequent mucous cell metaplasia/hyperplasia in the
respiratory tract mucosa [78, 79]. However, whether this is
true in the middle ear epithelium under the condition of
inﬂammation remains to be elucidated.
6.SignalingPathwaysinMucousCell
Metaplasia/Hyperplasia
It has been well established that bacterial signaling at
mucosal surfaces processes that aﬀect glycosylation in
the literature [80, 81]. There may be more than one
pathways involved in mucous cell metaplasia/hyperplasiaInternational Journal of Otolaryngology 7
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Figure 7: The middle ear mucosa in the wildtype (wt) mice responds to the challenge of nontypable H. inﬂuenzae (NTHi) and increases its
mucous cell number (c). The middle ear mucosa in the interleukin 10 (IL-10) knockout mutant (mt) mice exhibits fewer mucous cells in
response to NTHi infection (d). Arrows pointing to mucous cells.
of OM because of the importance of mucous cells in
physiology and innate immune defense against infections.
As described above, one well-recognized pathway is mid-
dle ear infection→inﬂammatory cell inﬁltration→cytokine
production→mucous cell metaplasia/hyperplasia [5, 58].
Whether there is an inﬂammatory cell-independent pathway
for mucous cell metaplasia in the middle ear was not known
until our recent studies showed that PGPS incubation with
mouse middle ear epithelial cells for 2 weeks in vitro led
to the development of mucous-like cells in a cell culture
system (referred to as Figure 9). This suggests that there are
inﬂammatory cell-dependent and -independent mucous cell
developmental pathways.
How mucous cells grow and diﬀerentiate in such a cell
culture system is unclear. However, this provides an excellent
model for the studies of mucous cell development. What
would be the receptors and signal molecules that mediate
the development of mucous cells? Firstly, TLRs are thought
as the ones that trigger the signaling pathway because they
specialize in recognition of bacterial pathogen-associated
molecular pattern (PAMP). Indeed, TLR2 mediates Gram+
bacteriaandtheirmetabolitesforactivationofhostcells[82].
TLR2 is expressed in mouse middle ear epithelial cells, and
PGPS upregulates the expression of TLR2 [82].
Pneumococcus has been shown to bind to polymeric
immunoglobulin A receptor (pIgAR) or platelet-activating
factor receptor (PAFR) and enters nasopharyngeal epithelial
cells through pIgAR [83] and lung epithelial cells through
PAFR [84], but these receptors do not appear to activate host
cells.
What would be the post-NF-κB signal transduction
cascade in terms of mucous cell development? It is unknown
atthemoment.RecentstudyindicatesthatId1isupregulated
by pneumococcus [24]. In transgenic mice, Id1 overexpres-
sion in mice resulted in adenoma (mucous cell dysplasia) in
the intestinal mucosa [85]. Transfection of mouse middle ear
epitheliuminvivowithId1foraweekcausestheproliferation
of middle ear epithelial cells including mucous cells [86].
Transfection of middle ear epithelial cells with Id1 for two
weeks followed by ETO for four weeks (a two-step method
for induction of middle ear eﬀusion) causes mucoid eﬀusion
in the middle ear cavity of rats [86].
It is generally accepted that withdrawal from cell cycle
is a prerequisite for cellular diﬀerentiation. It has been
observed that Id1 has a dual eﬀect on middle ear epithelial
cell proliferation. Within the ﬁrst 24h of transfection with
Id1, rats had increased DNA synthesis, cell cycle progres-
sion, and cell counts. After 24h, however, these cells had
decreased DNA synthesis, cell cycle progression, and cell
counts and downregulated the mucin promoter activities.
Correspondingly,transfectionofthemiddleearmucosawith
Id1 increased the epithelial cell number and mucous cell
counts (Figure 8).
Recent studies demonstrated that this process was asso-
ciated with an increased expression of the Math1 gene
[86], suggesting that Math1 plays an important role in the
diﬀerentiation of mucous cells. Indeed, Math1 potentiated
the expression of mucins in vitro (Figure 9).
Math1 belongs to one of the helix-loop-helix (HLH)
families and can form dimers with Id proteins and antag-
onize the eﬀects of Id proteins, thus resulting in cellular
diﬀerentiation. In referenced studies, Math1 is required for
the diﬀerentiation of progenitor cells into goblet cells in
the intestinal epithelium, and the loss of the Math1 gene8 International Journal of Otolaryngology
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Figure 8: Id1 induces the proliferation of middle ear epithelial cells ((f), H&E stain) and mucous cells (arrows, (h), AB-PAS stain) compared
with empty vector controls ((e), H&E, (g), AB-PAS). Note that the thickening of the middle ear epithelium is increased in Id1-transfected
animals ((f), between arrows) compared with empty vector-transfected controls (e).
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Figure 9:Math1playsanimportantroleinthediﬀerentiationofmucous-likecells.(a)WithMath1beingknockeddownbyantisense-Math1
(as-Math1), AB-PAS-positive cells are obviously reduced in cultured mouse middle ear epithelial cells. (b) With Math1 being upregulated by
sense-Math1 (s-Math1), AB-PAS-positive cells are remarkably increased. RA, retinoid acid; TNFα, tumor necrotic factor alpha.
leads to the depletion of goblet cells in the gut without
aﬀectingenterocytes[87].Thus,itispossiblethattheId1and
Math1, respectively, regulate mucous cell metaplasia in OM;
Id proteins trigger proliferation of progenitor mucous cells,
and Math1 is responsible for the subsequent mucous cell
diﬀerentiation. This notion is supported by in vivo studies in
which overexpression of Id1 in the middle ear of mice caused
epithelial cell hyperplasia and mucous cell metaplasia [86]
whereas overexpression of Math1 in the middle ear of mice
increased the mucous cell population [86].
On the basis of Math1, there are other factors which
are important in the diﬀerentiation of mucous cells. As
discussed above, multiple signaling pathways are involved in
the diﬀerentiation of mucous cells. These signaling pathways
are linked to inﬂammatory cytokines and/or physiological
factors. There are many cytokines/chemokines/growth fac-
tors, as mentioned above, especially those Th2 cytokines
that are frequently linked to the diﬀerentiation of mucous
cells. In general, factors that are essential for the diﬀeren-
tiation of mucous cells include fundamental transcription
factors such as Math1, proinﬂammatory mediator such as
TNFα, and epithelial cell diﬀerentiation factors such as
retinoid acid. Experimentally, the addition of these three
factors to cultured middle ear epithelial cells induces the
diﬀerentiation of mucous-like cells in vitro (referred to as
Figure 9).
In addition to Math1, other genes such as RELM-
beta/FIZZ2 and gob5 are also relevant [88, 89].International Journal of Otolaryngology 9
Mucous cell metaplasia remains to be a great challenge
for clinicians and researchers. There are no eﬀective means
of cure and prevention due to the lack of knowledge
about the pathogenic mechanism of mucous cell meta-
plasia/hyperplasia in OM. Identiﬁcation of the molecular
pathways that mediate mucous cell metaplasia will not only
facilitatetheunderstandingofOMpathobiologybutwillalso
help develop eﬀective means of prevention and treatment of
chronic OM.
7. FutureDirections
(1) Origin of mucous cells in the middle ear mucosa:
it is generally believed that all the epithelial cell
types, goblet cells, and ciliated cells, in the middle
ear mucosa, originate from middle ear epithelial
stem cells. Unfortunately, nothing is known about
the origin of epithelial stem cells in the middle ear
mucosa. Many eﬀorts and endeavors need to be
placed in this new area in order to understand how
mucous cells grow, proliferate, and diﬀerentiate into
the terminal mucous cells in the middle ear setting.
( 2 )I n i t i a lt r i g g e r so fm u c o u sc e l ld i ﬀerentiation: mutant
mice provide a chance to identify the genes that
are involved in the initial diﬀerentiation of mucous
cells. As mentioned above, Math1 may serve as a
trigger for initial diﬀerentiation of mucous cells. To
this end, Math1 conditional knockout mutant mice
are needed to prove whether Math1 is essential for
mucous cell metaplasia/hyperplasia in the middle ear
mucosa. If so, what is the next gene that pushes the
initial diﬀerentiation of mucous cells further toward
the terminal diﬀerentiation of mucous cells. In the
intestine, GFI1 and SPDEF are needed [90]. It is
unknown whether this is true to the middle ear.
(3) Therapeutic agents for blockage of mucous cell
metaplasia/hyperplasia: after identiﬁcation of the
mucous cell diﬀerentiation genes, otological scien-
tists should be able to study and identify agents
that can block mucous cell metaplasia/hyperplasia
based upon the understanding of the molecular
mechanism of mucous cell metaplasia/hyperplasia.
Much work needs to be done in this particular area
for identiﬁcation of eﬀective agents to stop mucous
cell metaplasia/hyperplasia in OM.
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